Treatment strategies to minimize or prevent chronic allograft dysfunction in pediatric renal transplant recipients: An overview

Pediatric Drugs

Volumn 11, Issue 6, 2009, Pages 381-396

  Höcker, Britta ^a   Tönshoff, Burkhard ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; CALCINEURIN INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIDOFOVIR; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GANCICLOVIR; IMMUNOGLOBULIN; LEFLUNOMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RITUXIMAB; TACROLIMUS;

ANTIBODY RESPONSE; ANTIHYPERTENSIVE ACTIVITY; AREA UNDER THE CURVE; AVOIDANCE BEHAVIOR; BLADDER SURGERY; BONE MARROW SUPPRESSION; CARDIOVASCULAR RISK; CATHETERIZATION; CHRONIC ALLOGRAFT NEPHROPATHY; CHRONIC DISEASE; CYTOMEGALOVIRUS; DRUG MEGADOSE; DRUG MONITORING; GRAFT REJECTION; GRAFT SURVIVAL; HISTOPATHOLOGY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGONADOTROPIC HYPOGONADISM; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ARTERY STENOSIS; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LOW DRUG DOSE; LOWER URINARY TRACT SYMPTOM; LYMPHOCYTE; NEPHROTOXICITY; NONHUMAN; OBSTRUCTION; POLYOMA VIRUS; PRIORITY JOURNAL; PROTEINURIA; PYELONEPHRITIS; RENAL ARTERY THROMBOSIS; RENAL PROTECTION; REVIEW; T LYMPHOCYTE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VIRUS INFECTION; WITHDRAWAL SYNDROME;

ANIMALS; CHILD; GRAFT REJECTION; HUMANS; KIDNEY; KIDNEY TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 70449442553     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.2165/11316100-000000000-00000     Document Type: Review

References (119)

1. Chapman JR, O'Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. J Am Soc Nephrol 2005; 16 (10): 3015-3026
2. North American Pediatric Renal Trials and Collaborative Studies. NAPRTCS 2006 annual report [online]. Available from URL: https://web. emmes.com/study/ped/annlrept/annlrept2006.pdf [Accessed 2009 Sep 1]
3. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349 (24): 2326-2333
4. Solez K, Colvin RB, Racusen LC, et al. Banff '05 meeting report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7 (3): 518-526
5. Poggio ED, Clemente M, Riley J, et al. Alloreactivity in renal transplant recipients with and without chronic allograft nephropathy. J Am Soc Nephrol 2004; 15 (7): 1952-1960
6. Krieger NR, Becker BN, Heisey DM, et al. Chronic allograft nephropathy uniformly affects recipients of cadaveric, nonidentical living-related, and living-unrelated grafts. Transplantation 2003; 75 (10): 1677-1682
7. Morrissey PE, Flynn ML, Lin S. Medication noncompliance and its implications in transplant recipients. Drugs 2007; 67 (10): 1463-1481
8. Randhawa PS, Minervini MI, Lombardero M, et al. Biopsy of marginal donor kidneys: correlation of histologic findings with graft dysfunction. Transplantation 2000; 69 (7): 1352-1357
9. Gasser M, Waaga AM, Laskowski IA, et al. The influence of donor brain death on short and long-term outcome of solid organ allografts. Ann Transplant 2000; 5 (4): 61-67
10. Buscher R, Vester U, Wingen AM, et al. Pathomechanisms and the diagnosis of arterial hypertension in pediatric renal allograft recipients. Pediatr Nephrol 2004; 19 (11): 1202-1211
11. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001; 59 (1): 260-269
12. Hatch DA, Koyle MA, Baskin LS, et al. Kidney transplantation in children with urinary diversion or bladder augmentation. J Urol 2001; 165 (6 Pt 2): 2265-2268
13. North American Pediatric Renal Trials and Collaborative Study. NAPRTCS 2004 annual report [online]. Available from URL: https://web.emmes.com/ study/ped/annlrept/annlrept2004.pdf [Accessed 2008 Feb 1]
14. Tönshoff B, Höcker B. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity. Pediatr Transplant 2006; 10 (6): 721-729
15. Bunchman TE, Fryd DS, Sibley RK, et al. Manifestations of renal allograft rejection in small children receiving adult kidneys. Pediatr Nephrol 1990; 4 (3): 255-258
16. Rush D. Protocol transplant biopsies: an underutilized tool in kidney transplantation. Clin J Am Soc Nephrol 2006; 1 (1): 138-143
17. Hymes LC, Greenbaum L, Amaral SG, et al. Surveillance renal transplant biopsies and subclinical rejection at three months post-transplant in pediatric recipients. Pediatr Transplant 2007; 11 (5): 536-539
18. Shapiro R, Starzl TE. Protocol biopsies should not (yet) be the standard of care in pediatric renal transplant recipients. Pediatr Transplant 2006; 10 (7): 766-767
19. Birk PE, Rush DN. Protocol biopsies should be standard of care for pediatric renal allograft recipients! Pediatr Transplant 2006; 10 (7): 760-765
20. RushD,Nickerson P,Gough J, et al. Beneficial effects of treatment of early subclinical rejection: a randomized study. J Am SocNephrol 1998; 9 (11): 2129-2134
21. Shishido S, Asanuma H, Nakai H, et al. The impact of repeated subclinical acute rejection on the progression of chronic allograft nephropathy. J Am Soc Nephrol 2003; 14 (4): 1046-1052
22. Kee TY, Chapman JR, O'Connell PJ, et al. Treatment of subclinical rejection diagnosed by protocol biopsy of kidney transplants. Transplantation 2006; 82 (1): 36-42
23. Rush D, Arlen D, Boucher A, et al. Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: a randomized study. Am J Transplant 2007; 7 (11): 2538-2545
24. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723 (Pubitemid 29082898)
25. Seikku P, Krogerus L, Jalanko H, et al. Better renal function with enhanced immunosuppression and protocol biopsies after kidney transplantation in children. Pediatr Transplant 2005; 9 (6): 754-762
26. Tönshoff B, Melk A. Immunosuppression in pediatric kidney transplantation. In: Geary DF, Schaefer F, editors. Comprehensive pediatric nephrology. Philadelphia (PA): Mosby Elsevier, 2008: 905-929
27. Worthington JE, McEwen A,McWilliam LJ, et al. Association between C4d staining in renal transplant biopsies, production of donor-specific HLA antibodies, and graft outcome. Transplantation 2007; 83 (4): 398-403
28. David-Neto E, Prado E, Beutel A, et al. C4d-positive chronic rejection: a frequent entity with a poor outcome. Transplantation 2007; 84 (11): 1391-1398
29. Billing H, Rieger S, Ovens J, et al. Successful treatment of chronic antibodymediated rejection with IVIG and rituximab in pediatric renal transplant recipients. Transplantation 2008; 86 (9): 1214-1221
30. Feber J, Wong H, Geier P, et al. Complications of chronic kidney disease in children post-renal transplantation: a single center experience. Pediatr Transplant 2008 Feb; 12 (1): 80-84
31. White CT, Schisler T, Er L, et al. CKD following kidney transplantation in children and adolescents. Am J Kidney Dis 2008; 51 (6): 996-1004
32. Mitsnefes MM. Hypertension and end-organ damage in pediatric renal transplantation. Pediatr Transplant 2004; 8 (4): 394-399
33. Opelz G, Döhler B, Collaborative Transplant Study. Improved long-term outcomes after renal transplantation associated with blood pressure control. Am J Transplant 2005; 5 (11): 2725-2731
34. Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACEinhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999; 354 (9176): 359-364
35. Giatras I, Lau J, Levey AS. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. Ann Intern Med 1997; 127 (5): 337-345
36. Wühl E, Mehls O, Schaefer F, ESCAPE Trial Group. Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure. Kidney Int 2004; 66 (2): 768-776 (Pubitemid 38982021)
37. Reinberg Y, Gonzalez R, Fryd D, et al. The outcome of renal transplantation in children with posterior urethral valves. J Urol 1988; 140 (6): 1491-1493
38. Bryant JE, Joseph DB, Kohaut EC, et al. Renal transplantation in children with posterior urethral valves. J Urol 1991; 146 (6): 1585-1587
39. Luke PP, Herz DB, Bellinger MF, et al. Long-term results of pediatric renal transplantation into a dysfunctional lower urinary tract. Transplantation 2003; 76 (11): 1578-1582
40. Rigamonti W, Capizzi A, Zacchello G, et al. Kidney transplantation into bladder augmentation or urinary diversion: long-term results. Transplantation 2005; 80 (10): 1435-1440
41. Nahas WC, Antonopoulos IM, Piovesan AC, et al. Comparison of renal transplantation outcomes in children with and without bladder dysfunction: a customized approach equals the difference. J Urol 2008; 179 (2): 712-716
42. Kamath NS, John GT, Neelakantan N, et al. Acute graft pyelonephritis following renal transplantation. Transpl Infect Dis 2006; 8 (3): 140-147
43. Dunn SP, Vinocur CD, Hanevold C, et al. Pyelonephritis following pediatric renal transplant: increased incidence with vesicoureteral reflux. J Pediatr Surg 1987; 22 (12): 1095-1099
44. Neuhaus TJ, Schwöbel M, Schlumpf R, et al. Pyelonephritis and vesicoureteral reflux after renal transplantation in young children. J Urol 1997; 157 (4): 1400-1403
45. Dharnidharka VR, Agodoa LY, Abbott KC. Risk factors for hospitalization for bacterial or viral infection in renal transplant recipients: an analysis of USRDS data. Am J Transplant 2007; 7 (3): 653-661
46. Dharnidharka VR, Agodoa LY, Abbott KC. Effects of urinary tract infection on outcomes after renal transplantation in children. Clin J Am Soc Nephrol 2007; 2 (1): 100-106
47. John U, Everding AS, Kuwertz-Bröking E, et al. High prevalence of febrile urinary tract infections after paediatric renal transplantation. Nephrol Dial Transplant 2006; 21 (11): 3269-3274
48. Kim SS, Hicks J, Goldstein SL. Adenovirus pyelonephritis in a pediatric renal transplant patient. Pediatr Nephrol 2003; 18 (5): 457-461
49. Keswani M, Moudgil A. Adenovirus-associated hemorrhagic cystitis in a pediatric renal transplant recipient. Pediatr Transplant 2007; 11 (5): 568-571
50. HelanteräI, Koskinen P, Finne P, et al. Persistent cytomegalovirus infection in kidney allografts is associated with inferior graft function and survival. Transpl Int 2006; 19 (11): 893-900
51. Il'inski IM, Rotova ID, Kurenkova LG, et al. Cytomegalovirus infection of allografted kidneys in children. Vestn Ross Akad MedNauk 2006; (11): 46-49
52. Bock GH, Sullivan EK, Miller D, et al. Cytomegalovirus infections following renal transplantation-effects on antiviral prophylaxis: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Nephrol 1997; 11 (6): 665-671
53. Ginevri F, Losurdo G, Fontana I, et al. Acyclovir plusCMVimmunoglobulin prophylaxis and early therapy with ganciclovir are effective and safe inCMV high-risk renal transplant pediatric recipients. Transpl Int 1998; 11 Suppl. 1: S130-4
54. Melgosa Hijosa M, García Meseguer C, Peña Garcia P, et al. Preemptive treatment with oral ganciclovir for pediatric renal transplantation. Clin Nephrol 2004; 61 (4): 246-252
55. Li L, Chaudhuri A, Weintraub LA, et al. Subclinical cytomegalovirus and Epstein-Barr virus viremia are associated with adverse outcomes in pediatric renal transplantation. Pediatr Transplant 2007; 11 (2): 187-195
56. Hirsch HH, Steiger J. Polyomavirus BK. Lancet Infect Dis 2003; 3 (10): 611-623
57. Hirsch HH, Drachenberg CB, Steiger J, et al. Polyomavirus-associated nephropathy in renal transplantation: critical issues of screening and management. Adv Exp Med Biol 2006; 577: 160-173
58. Acott PD. Polyoma virus in pediatric renal transplantation. Pediatr Transplant 2006; 10 (7): 856-860
59. Hariharan S. BK virus nephritis after renal transplantation. Kidney Int 2006; 69 (4): 655-662
60. Ahuja M, Cohen EP, Dayer AM, et al. Polyoma virus infection after renal transplantation: use of immunostaining as a guide to diagnosis. Transplantation 2001; 71 (7): 896-899
61. Rajpoot DK, Gomez A, Tsang W, et al. Ureteric and urethral stenosis: a complication of BK virus infection in a pediatric renal transplant patient. Pediatr Transplant 2007; 11 (4): 433-435
62. Herman J, Van Ranst M, Snoeck R, et al. Polyomavirus infection in pediatric renal transplant recipients: evaluation using a quantitative real-time PCR technique. Pediatr Transplant 2004; 8 (5): 485-492
63. Smith JM, McDonald RA, Finn LS, et al. Polyomavirus nephropathy in pediatric kidney transplant recipients.AmJ Transplant 2004; 4 (12): 2109-2117
64. Smith JM, Dharnidharka VR, Talley L, et al. BK virus nephropathy in pediatric renal transplant recipients: an analysis of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) registry. Clin J Am Soc Nephrol 2007; 2 (5): 1037-1042
65. Schmitz M, Brause M, Hetzel G, et al. Infection with polyomavirus type BK after renal transplantation. Clin Nephrol 2003; 60 (2): 125-129
66. Trofe J, Hirsch HH, Ramos E. Polyomavirus-associated nephropathy: update of clinical management in kidney transplant patients. Transpl Infect Dis 2006; 8 (2): 76-85
67. Brennan DC, Agha I, Bohl DL, et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 2005; 5 (3): 582-594
68. Kadambi PV, Josephson MA, Williams J, et al. Treatment of refractory BK virus-associated nephropathy with cidofovir. Am J Transplant 2003; 3 (2): 186-191
69. Williams JW, Javaid B, Kadambi PV, et al. Leflunomide for polyomavirus type BK nephropathy. N Engl J Med 2005; 352 (11): 1157-1158
70. Vats A, Shapiro R, Singh Randhawa P, et al. Quantitative viral load monitoring and cidofovir therapy for the management of BK virus-associated nephropathy in children and adults. Transplantation 2003; 75 (1): 105-112
71. Hirsch HH, Ramos E. Retransplantation after polyomavirus-associated nephropathy: just do it? Am J Transplant 2006; 6 (1): 7-9
72. Olyaei AJ, de Mattos AM, Bennett WM. Immunosuppressant-induced nephropathy: pathophysiology, incidence and management. Drug Saf 1999; 21 (6): 471-488
73. Filler G, Webb NJ, Milford DV, et al. Four-year data after pediatric renal transplantation: a randomized trial of tacrolimus vs cyclosporin microemulsion. Pediatr Transplant 2005; 9 (4): 498-503
74. Matl I, Viklický O, Voska L, et al. The effect of different immunosuppressive regimens on TGF-beta1 expression in kidney transplant patients. Transpl Int 2005; 18 (6): 668-671
75. Neu AM, Ho PL, Fine RN, et al. Tacrolimus vs cyclosporine A as primary immunosuppression in pediatric renal transplantation: a NAPRTCS study. Pediatr Transplant 2003; 7 (3): 217-222
76. Stoves J, Newstead CG, Baczkowski AJ, et al. A randomized controlled trial of immunosuppression conversion for the treatment of chronic allograft nephropathy. Nephrol Dial Transplant 2004; 19 (8): 2113-2120
77. Meier M, NitschkeM,Weidtmann B, et al. Slowing the progression of chronic allograft nephropathy by conversion from cyclosporine to tacrolimus: a randomized controlled trial. Transplantation 2006; 81 (7): 1035-1040
78. Shihab FS, Waid TH, Conti DJ, et al. Conversion from cyclosporine to tacrolimus in patients at risk for chronic renal allograft failure: 60-month results of the CRAF Study. CRAF Study Group. Transplantation 2008; 85 (9): 1261-1269
79. Vincenti F, Ramos E, Brattstrom C, et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001; 71 (9): 1282-1287
80. Groth CG, Bäckman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67 (7): 1036-1042
81. Kreis H, Cisterne JM, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69 (7): 1252-1260
82. Morales JM, Wramner L, Kreis H, et al. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Sirolimus European Renal Transplant Study Group. Am J Transplant 2002; 2 (5): 436-442
83. Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74 (8): 1070-1076
84. Larson TS, Dean PG, Stegall MD, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6 (3): 514-522
85. Srinivas TR, Schold JD, Guerra G, et al. Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation. Am J Transplant 2007; 7 (3): 586-594
86. Harmon W, Meyers K, Ingelfinger J, et al. Safety and efficacy of a calcineurin inhibitor avoidance regimen in pediatric renal transplantation. J Am Soc Nephrol 2006; 17 (6): 1735-1745
87. Abramowicz D, Manas D, Lao M, et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study. Cyclosporine Withdrawal Study Group. Transplantation 2002; 74 (12): 1725-1734
88. Abramowicz D, Del Carmen Rial M, Vitko S, et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. Cyclosporine Withdrawal Study Group. J Am Soc Nephrol 2005; 16 (7): 2234-2240
89. Schnuelle P, van der Heide JH, Tegzess A, et al. Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen. J Am Soc Nephrol 2002; 13 (2): 536-543
90. Smak Gregoor PJ, vanGelder T, van Besouw NM, et al. Randomized study on the conversion of treatment with cyclosporine to azathioprine or mycophenolate mofetil followed by dose reduction. Transplantation 2000; 70 (1): 143-148
91. Dudley C, Pohanka E, Riad H, et al. Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the ''creeping creatinine'' study. Mycophenolate Mofetil Creeping Creatinine Study Group. Transplantation 2005; 79 (4): 466-475
92. Tapia E, Franco M, Sá nchez-Lozada LG, et al. Mycophenolate mofetil prevents arteriolopathy and renal injury in subtotal ablation despite persistent hypertension. Kidney Int 2003; 63 (3): 994-1002
93. Ferraris JR, Tambutti ML, Redal MA, et al. Conversion from azathioprine to mycophenolate mofetil in pediatric renal transplant recipients with chronic rejection. Transplantation 2000; 70 (2): 297-301
94. Filler G, Gellermann J, Zimmering M, et al. Effect of adding mycophenolate mofetil in paediatric renal transplant recipients with chronical cyclosporine nephrotoxicity. Transpl Int 2000; 13 (3): 201-206
95. David-Neto E, Araujo LM, Lemos FC, et al. Introduction of mycophenolate mofetil and cyclosporin reduction in children with chronic transplant nephropathy. Pediatr Transplant 2001; 5 (4): 302-309
96. Ibá ñez JP, Monteverde ML, Goldberg J, et al. Sirolimus in pediatric renal transplantation. Transplant Proc 2005; 37 (2): 682-684
97. Powell HR, Kara T, Jones CL. Early experience with conversion to sirolimus in a pediatric renal transplant population. Pediatr Nephrol 2007; 22 (10): 1773-1777
98. Falger JC, Mueller T, Arbeiter K, et al. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy. Pediatr Transplant 2006; 10 (4): 474-478
99. Vilalta R, Vila A, Nieto J, et al. Rapamycin use and rapid withdrawal of calcineurin inhibitors in pediatric renal transplantation. Transplant Proc 2003; 35 (2): 703-704
100. Höcker B, Feneberg R, Köpf S, et al. SRL-based immunosuppression vs CNI minimization in pediatric renal transplant recipients with chronic CNI nephrotoxicity. Pediatr Transplant 2006; 10 (5): 593-601
101. Butani L. Investigation of pediatric renal transplant recipients with heavy proteinuria after sirolimus rescue. Transplantation 2004; 78 (9): 1362-1366
102. Höcker B, Knüppel T, Waldherr R, et al. Recurrence of proteinuria 10 years post-transplant in NPHS2-associated focal segmental glomerulosclerosis after conversion from cyclosporin A to sirolimus. Pediatr Nephrol 2006; 21 (10): 1476-1479
103. Diekmann F, Budde K, Oppenheimer F, et al. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004; 4 (11): 1869-1875 (Pubitemid 39434449)
104. Huyghe E, Zairi A, Nohra J, et al. Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: an overview. Transpl Int 2007; 20 (4): 305-311
105. Ekberg H, Grinyó J, Nashan B, et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR study. Am J Transplant 2007; 7 (3): 560-570
106. Weir MR, Blahut S, Drachenburg C, et al. Late calcineurin inhibitor withdrawal as a strategy to prevent graft loss in patients with suboptimal kidney transplant function. Am J Nephrol 2004; 24 (4): 379-386
107. Frimat L, Cassuto-Viguier E, Charpentier B, et al. Impact of cyclosporine reduction with MMF: a randomized trial in chronic allograft dysfunction. The 'reference' study. Am J Transplant 2006; 6 (11): 2725-2734
108. Benz K, Plank C, Griebel M, et al. Mycophenolate mofetil introduction stabilizes and subsequent cyclosporine A reduction slightly improves kidney function in pediatric renal transplant patients: a retrospective analysis. Pediatr Transplant 2006; 10 (3): 331-336
109. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation: ELITE-Symphony study. N Engl J Med 2007; 357 (25): 2562-2575
110. Oellerich M, Armstrong VW. Two-hour cyclosporine concentration determination: an appropriate tool to monitor neoral therapy? Ther Drug Monit 2002; 24: 40-46
111. Levy GA. C2 monitoring strategy for optimising cyclosporin immunosuppression from the Neoral formulation. BioDrugs 2001; 15 (5): 279-290
112. Weber LT, Armstrong VW, Shipkova M, et al. Cyclosporin A absorption profiles in pediatric renal transplant recipients predict the risk of acute rejection. Ther Drug Monit 2004; 26 (4): 415-424
113. Weber LT, Shipkova M, Armstrong VW, et al. The pharmacokineticpharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German study group on mycophenolate mofetil therapy. J Am Soc Nephrol 2002; 13 (3): 759-768
114. Van Gelder T, Meur YL, Shaw LM, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006; 28: 145-154
115. Van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized doubleblind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999; 68 (2): 261-266
116. Weber LT, Hoecker B, Armstrong VW, et al. Validation of an abbreviated pharmacokinetic profile for the estimation ofmycophenolic acid exposure in pediatric renal transplant recipients. Ther Drug Monit 2006; 28 (5): 623-631
117. Filler G, Mai I. Limited sampling strategy for mycophenolic acid area under the curve. Ther Drug Monit 2000; 22 (2): 169-173
118. Aspeslet LJ, Yatscoff RW. Requirements for therapeutic drug monitoring of sirolimus, an immunosuppressive agent used in renal transplantation. Clin Ther 2000; 22 Suppl. B: B86-92
119. Package insert (European label) of Rapamune-, PAA004708 [online]. Available from URL: http://www.rapamune.de/fachinfos.html [Accessed 2009 Sep 15]